The launch of the bispecific DLL3/CD3 antibody Tarlatamab marks a significant turning point for targeting DLL3.

Pierre Fabre Laboratories gets green light from EC for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) combo to treat adults with advanced BRAFV600E-mutant NSCLC.

Alnylam Shares In-Depth Findings from Successful Phase 3 HELIOS-B Study of Vutrisiran in ATTR Amyloidosis Cardiomyopathy Patients at ESC Congress.

Sep 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Orgenesis Reports Favorable Outcomes from a Practical Study on ORG-101 CAR-T Treatment in CD19+ Acute Lymphoblastic Leukemia Patients.

Johnson & Johnson aims for initial approval of nipocalimab to treat a wide range of patients with antibody-positive generalized myasthenia gravis.

Patsnap Bio, with its chemical modification search function, provides users with a powerful tool for exploring multidimensional nucleotide sequence information.

Merck has recently divulged advancements pertaining to two pivotal Phase 3 clinical trials, designated as KEYNOTE-867 and KEYNOTE-630.

at the ESC Congress, Bayer published the pooled analysis of the Phase III FINE-HEART study on finerenone, along with the latest data from the FINEARTS-HF trial.

Rallybio Unveils RLYB212's Phase 1 Exploratory Study Outcomes in Blood Clotting & Coagulation Dynamics.

Sep 3rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Bayer has disclosed the enrollment of the inaugural patient into the international Phase III SOHO-02 study, a randomized, open-label, multicenter clinical endeavor.